{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:32:54Z","timestamp":1790681574361,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11523-020-00770-6","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T05:03:09Z","timestamp":1604552589000},"page":"723-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Jacques","family":"Raphael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Helou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Boldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Vandenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip S","family":"Blanchette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"issue":"2","key":"770_CR1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10549-014-3145-x","volume":"148","author":"A Alqaisi","year":"2014","unstructured":"Alqaisi A, Chen L, Romond E, Chambers M, Stevens M, Pasley G, et al. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. Breast Cancer Res Treat. 2014;148(2):437\u201344.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"770_CR2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393.","journal-title":"Cell"},{"issue":"6","key":"770_CR3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/bcr3039","volume":"13","author":"TW Miller","year":"2011","unstructured":"Miller TW, Rexer BN, Garrett JT, Arteaga C. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13(6):224.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"770_CR4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550\u201362.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"770_CR5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/s12885-016-2609-2","volume":"16","author":"QB She","year":"2016","unstructured":"She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, et al. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN\/PI3K and EGFR pathways for basal-like breast cancer. BMC Cancer. 2016;16(1):587.","journal-title":"BMC Cancer"},{"key":"770_CR6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/OTT.S76116","volume":"8","author":"J Li","year":"2015","unstructured":"Li J, Zhang C, Jiang H, Cheng J. Andrographolide inhibits hypoxia-inducible factor-1 through phosphatidylinositol 3-kinase\/AKT pathway and suppresses breast cancer growth. Onco Targets Ther. 2015;8:427\u201335.","journal-title":"Onco Targets Ther"},{"issue":"8","key":"770_CR7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/01.cad.0000173476.67239.3b","volume":"16","author":"D Morgensztern","year":"2005","unstructured":"Morgensztern D, McLeod HL. PI3K\/Akt\/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16(8):797\u2013803.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"770_CR8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1758834014530023","volume":"6","author":"E Paplomata","year":"2014","unstructured":"Paplomata E, O\u2019Regan R. The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6(4):154\u201366.","journal-title":"Ther Adv Med Oncol."},{"issue":"10","key":"770_CR9","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, Burris H, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013a;30(10):870\u201384.","journal-title":"Adv Ther."},{"key":"770_CR10","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014."},{"issue":"7","key":"770_CR11","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.","journal-title":"PLoS Med"},{"key":"770_CR12","volume-title":"AJCC cancer staging manual","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.","edition":"7"},{"key":"770_CR13","volume-title":"AJCC cancer staging manual","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.","edition":"8"},{"issue":"2","key":"770_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts X, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"key":"770_CR15","unstructured":"Common Terminology Criteria for AdverseEvents version 3.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed 9 Aug 2006."},{"key":"770_CR16","unstructured":"https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 9 Aug 2006."},{"key":"770_CR17","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011."},{"key":"770_CR18","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Sterne JAC, Savovi\u0107 J, Page MJ, Hr\u00f3bjartsson A, Boutron I, Reeves B, Eldridge S. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane methods. Cochrane Database of Systematic Reviews 2016; no 10 (Suppl 1). https:\/\/doi.org\/10.1002\/14651858.CD201601.","DOI":"10.1002\/14651858.CD201601"},{"issue":"7454","key":"770_CR19","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.","journal-title":"BMJ"},{"key":"770_CR20","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. 2013. The GRADE Working Group; 2013. https:\/\/guidelinedevelopment.org\/handbook."},{"issue":"3","key":"770_CR21","doi-asserted-by":"crossref","first-page":"177e88","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177e88.","journal-title":"Control Clin Trials"},{"key":"770_CR22","unstructured":"Deeks J, Higgins J, Altman D. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration. Wiley, New York; 2011."},{"issue":"7","key":"770_CR23","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","volume":"16","author":"SA Hurvitz","year":"2015","unstructured":"Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2 positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015;16(7):816\u201329.","journal-title":"Lancet Oncol."},{"issue":"6","key":"770_CR24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520\u20139.","journal-title":"N Engl J Med."},{"issue":"10","key":"770_CR25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2final progression-free survival analysis. Adv Ther. 2013b;30(10):870\u201384.","journal-title":"Adv Ther."},{"issue":"12","key":"770_CR26","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","volume":"25","author":"M Piccart","year":"2014","unstructured":"Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factorreceptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25(12):2357\u201362.","journal-title":"Ann Oncol."},{"issue":"4","key":"770_CR27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/annonc\/mdu009","volume":"25","author":"HS Rugo","year":"2014","unstructured":"Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol. 2014;25(4):808\u201315.","journal-title":"Ann Oncol."},{"issue":"6","key":"770_CR28","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","volume":"15","author":"F Andr\u00e9","year":"2014","unstructured":"Andr\u00e9 F, O\u2019Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580\u201391.","journal-title":"Lancet Oncol."},{"issue":"22","key":"770_CR29","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","volume":"30","author":"T Bachelot","year":"2012","unstructured":"Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancerwith prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30(22):2718\u201324.","journal-title":"J Clin Oncol."},{"issue":"16","key":"770_CR30","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2017.76.9331","volume":"36","author":"N Kornblum","year":"2018","unstructured":"Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, et al. Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negativemetastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol. 2018;36(16):1556\u201363.","journal-title":"J Clin Oncol."},{"issue":"1","key":"770_CR31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10549-015-3599-5","volume":"154","author":"DA Yardley","year":"2015","unstructured":"Yardley DA, Bosserman LD, O\u2019Shaughnessy JA, Harwin WN, Morgan SK, Priego VM, et al. Paclitaxel, bevacizumab, and everolimus\/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute. Breast Cancer Res Treat. 2015;154(1):89\u201397.","journal-title":"Breast Cancer Res Treat."},{"issue":"11","key":"770_CR32","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jamaoncol.2019.2526","volume":"5","author":"P Schmid","year":"2019","unstructured":"Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, et al. Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer: the manta phase 2 randomized clinical trial. JAMA Oncol.\u00a02019;5(11):1556\u201363.","journal-title":"JAMA Oncol."},{"issue":"3","key":"770_CR33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10549-019-05280-2","volume":"176","author":"T Decker","year":"2019","unstructured":"Decker T, Marschner N, Muendlein A, Welt A, Hagen V, Rauh J, et al. VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer. Breast Cancer Res Treat. 2019;176(3):637\u201347.","journal-title":"Breast Cancer Res Treat"},{"key":"770_CR34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-012-2067-8","volume":"135","author":"R Nahta","year":"2012","unstructured":"Nahta R, O\u2019Regan RM. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat. 2012;135:39\u201348.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"770_CR35","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(19)30420-6","volume":"20","author":"M Giuliano","year":"2019","unstructured":"Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360\u20139.","journal-title":"Lancet Oncol."},{"issue":"5","key":"770_CR36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18(5):654\u201362.","journal-title":"Lancet Oncol."},{"issue":"10","key":"770_CR37","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cncr.28010","volume":"119","author":"HA Burris 3rd","year":"2013","unstructured":"Burris HA 3rd, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013;119(10):1908\u201315.","journal-title":"Cancer"},{"issue":"4","key":"770_CR38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with Ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307\u201316.","journal-title":"N Engl J Med."},{"issue":"6","key":"770_CR39","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with Ribociclib plus Fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514\u201324.","journal-title":"N Engl J Med."},{"issue":"1","key":"770_CR40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2019","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of\u00a0abemaciclib\u00a0plus fulvestrant on overall\u00a0survival\u00a0in hormone receptor-positive, erbb2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol.\u00a02020;6(1):116\u201324.","journal-title":"JAMA Oncol"},{"issue":"3","key":"770_CR41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319.","journal-title":"N Engl J Med."},{"issue":"20","key":"770_CR42","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925\u201336.","journal-title":"N Engl J Med."},{"issue":"20","key":"770_CR43","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929\u201340.","journal-title":"N Engl J Med."},{"issue":"7","key":"770_CR44","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","volume":"18","author":"J Baselga","year":"2017","unstructured":"Baselga J, Im SA, Iwata H, Cortes J, De Laurentiis M, Jiang Z, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(7):904\u201316.","journal-title":"Lancet Oncol."},{"issue":"1","key":"770_CR45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","volume":"19","author":"A Di Leo","year":"2018","unstructured":"Di Leo A, Johnston S, Lee KS, Ciruelos E, Lonning PE, Janni W, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(1):87\u2013100.","journal-title":"Lancet Oncol."},{"key":"770_CR46","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-16-2653","volume":"77","author":"VM Jansen","year":"2017","unstructured":"Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, et al. Kinoma-wide RNA inferference screen reveals a role for PDK1K in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer. Cancer Res. 2017;77:2488\u201399.","journal-title":"Cancer Res."},{"issue":"2","key":"770_CR47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.currproblcancer.2018.08.009","volume":"43","author":"N Wang","year":"2019","unstructured":"Wang N, Wang K, Liu YT, Song FX. Everolimus plus endocrine vs endocrine therapy in treatment advanced ER+, HER2\u2212 breast cancer patients: A meta-analysis. Curr Probl Cancer. 2019;43(2):106\u201314.","journal-title":"Curr Probl Cancer."},{"key":"770_CR48","doi-asserted-by":"crossref","first-page":"e53292","DOI":"10.1371\/journal.pone.0053292","volume":"8","author":"S Loi","year":"2013","unstructured":"Loi S, Michiels S, Baselga J, Bartlett JMS, Singhal SK, Sabine VS, et al. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS ONE. 2013;8:e53292.","journal-title":"PLoS ONE"},{"key":"770_CR49","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1200\/JCO.2013.53.8272","volume":"32","author":"VS Sabine","year":"2014","unstructured":"Sabine VS, Crozier C, Brookes CL, Drake C, Piper T, van de Velde CJH, et al. Mutational analysis of PI3K\/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol. 2014;32:2951\u20138.","journal-title":"J Clin Oncol."},{"issue":"5","key":"770_CR50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","volume":"34","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, Pritchard KI, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2016;34(5):419\u201326.","journal-title":"J Clin Oncol."},{"issue":"15 suppl","key":"770_CR51","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1200\/JCO.2019.37.15_suppl.1024","volume":"37","author":"TD Bachelot","year":"2019","unstructured":"Bachelot TD, Treilleux I, Schiffler C, Bieche I, Campone M, Patsouris A, et al. mTORC1 activation assessed in metastatic sample to predict outcome in patients with metastatic breast cancer treated with everolimus-exemestan: results from the SAFIRTOR study. J Clin Oncol. 2019;37(15 suppl):1024\u20131024.","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-020-00770-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T09:09:38Z","timestamp":1608023378000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-020-00770-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00770-6","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]},"assertion":[{"value":"5 November 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jacques\u00a0Raphael has received honorarium (Hoffmann-La Roche) and participated on an advisory board for Lilly Oncology. Cory Lefebvre, Alison Allan, Joelle Helou, Gabriel Boldt, Theodore Vandenberg, and Phillip S. Blanchette have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable<b>.<\/b>","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JR had the idea for the systemic review; JR, C.L, GB performed the literature search and data analysis, JR, CL, GB, JH, A.A, PB, and TV drafted and critically revised the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}